This is a working overview of Dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Mean Green – Big, bold flavor inspired by the original black and green Monster Energy can. White Haze – A smooth, citrusy flavor with a clean finish. Peach Perfect – A crisp and refreshing peach blend. Scary Berries – A sparkling citrus and berry mix with less sweetness. Killer Sunrise – A bold citrus punch designed for all-day partying. Gnarly Grape – A juicy grape flavor with a bold finish. Pink Poison – A sweet and tangy blend with a vibrant profile. Later in 2023, Monster introduced the Nasty Beast line, a series of hard iced tea beverages targeting the flavored malt beverage market and competing with brands like Twisted Tea. Like The Beast Unleashed, these contain 6.0% ABV. Nasty Beast flavors include:
In August 2019, BASF agreed to sell its global pigments business to Japanese fine chemical company DIC for €1.15 billion ($1.28 billion) on a cash and debt-free basis. In September 2019, BASF signed an agreement with DuPont Safety & Construction, a subsidiary business unit of DuPont, to sell its ultrafiltration membrane business, Inge GmbH. According to BASF executives, Inge GmbH and its products fit better with DuPont and their business strategy. In February 2023, BASF announced that the company is planning to close one of its two ammonia factories at its site in Ludwigshafen, this comes as part of the companies plans to cut costs as the organisation has struggled with high energy costs. The result of the organisations plans will lead to increased production in China while resulting in the loss of 2,600 jobs. The Zhanjiang plant extends over 400 hectares and serves mainly the electronic industry and the automotive industry. In September 2023 BASF broke ground on its Zhanjiang syngas plant; the plant was due to be commissioned by 2025. In November 2023 the firm closed a $5bn 15-year investment deal in China, with Chinese banks. As of April 2023, BASF had 30 production facilities in China. CEO Martin Brudermüller held that Chinese revenue is essential to grow his European business in the face of "Europe’s high energy costs and stringent environmental rules."
Pennyroyal is toxic to humans and has differing effects dependent on the volume and concentration ingested. The most concentrated and toxic form of the pennyroyal plant is pennyroyal oil. The oil contains pulegone (a cyclohexanone), the molecule found in the highest concentration (80-92%) in the pennyroyal plant. Pulegone causes a variety of ailments in those who ingest it and is what causes the plant to have its peppermint flavor. Symptoms that may persist after ingesting a small dose (<10 mL) of pennyroyal oil are nausea, vomiting, abdominal pain and dizziness. Larger volumes may result in multiorgan failure that could lead to death. There are no current toxicokinetics studies performed on humans for the effects of pulegone, but there are some studies performed on other mammals. When pulegone is ingested, it is broken down by the liver and reacts to form multiple toxic metabolites that can wreak havoc in the body. Some identified metabolites are menthofuran, piperitenone, piperitone, and menthone. As little as 10 mL of pennyroyal oil ingestion was associated with moderate to severe hepatic toxicity.
=== UNGASS guidance === Three Special Session of the United Nations General Assembly (UNGASS) sessions have been held on the subject of drugs: "Drug abuse" (1990), "World drug problem" (1998), and "World drug problem" (2016). These high-level gatherings, involving heads of state and ministers, are documented usually in the form of a political declaration, an action plan, or a strategy that provide additional treaty guidance. These sessions can indicate whether the status quo will be maintained or if there is a broad openness to reform. In March 2016, the INCB stated that the UN drug treaties do not mandate a "war on drugs" and that the choice is not between "'militarized' drug law enforcement on one hand and the legalization of non-medical use of drugs on the other", health and welfare should be the focus of drug policy. That April, at the UNGASS on the "World drug problem", the Wall Street Journal assessed the attendees' positions as "somewhat" in two camps: "Some European and South American countries as well as the U.S. favored softer approaches.
== Low-energy CID and high-energy CID == Low-energy CID is typically carried out with ion kinetic energies less than approximately 1 kiloelectron volt (1 keV). Low-energy CID is highly efficient in fragmenting the selected precursor ions, but the type of fragment ions observed in low-energy CID is strongly dependent on the ion kinetic energy. Very low collision energies favor ion structure rearrangement, and the probability of direct bond cleavage increases as ion kinetic energy increases, leading to higher ion internal energies. High-energy CID (HECID) is carried out in magnetic sector mass spectrometers or tandem magnetic sector mass spectrometers and in tandem time-of-flight mass spectrometers (TOF/TOF). High-energy CID involves ion kinetic energies in the kilovolt range (typically 1 keV to 20 keV). High-energy CID can produce some types of fragment ions that are not formed in low-energy CID, such as charge-remote fragmentation in molecules with hydrocarbon substructures or sidechain fragmentation in peptides.
Sources: en.wikipedia.org
=== Pharmacokinetics === A study comprehensively reviewed the metabolism of 3-HO-PCE by using human liver microsomes and samples, both biological and non-biological, from a volunteer. The first major metabolic pathway involves N-dealkylation, yielding the primary amine metabolite 3-HO-PCA. The second pathway causes the molecule to undergo oxidation, creating phenol-3-HO-PCE and hydroxy-3-HO-PCE. These compounds then undergo dehydration, creating dehydro-3-HO-PCE (which is also created directly from the parent compound via dehydrogenation). The third pathway causes the parent compound to undergo oxidative deamination, creating 1-(3'-hydroxyphenyl) cyclohexanol. This compound can either undergo oxidation and dehydrogenation to form dihydroxy-[1,1'-bi(cyclohexan)]-1-en-3-one, or a pathway involving dehydration and allylic oxidation to eventually form 3'4'-dihydro-[1,1'-biphenyl]-3-ol. The fourth pathway is phase II conjugation, where the parent compound undergoes O-glucuronidation to form 3-OGlu-PCE.
== Career == Thomsen worked as a pharmacologist at Leo Pharma from 1989 to 1991 and was thereafter employed by Novo Nordisk in as head of Growth Hormone Research. He became senior vice president for diabetes R&D in 1994 and was appointed senior vice president of Health Care Discovery in 1995. In November 2000, he was appointed executive vice president of Global R&D and chief scientific officer (CSO). As chief scientific officer, he was responsible for the research and development of 20 medicine products within diabetes, obesity and biopharmaceuticals. He led the development of GLP-1 therapies that today are among the leading treatments within type 2 diabetes and obesity. He left the position as executive vice president of R&D on February 28, 2021, and took the role as CEO of the Novo Nordisk Foundation on March 1, 2021. He has been the president of the Danish Academy of Technical Sciences and has been on the board of directors at the Technical University of Denmark (DTU) and University of Copenhagen. From 2017 to 2020, Thomsen was the chairman of the board of directors at University of Copenhagen. Mads Krogsgaard Thomsen received the royal decoration of Knight of the Order of the Dannebrog by the Danish Royal House on 12 December 2022. In 2024, Thomsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer.
=== FAB based interfaces === The first fast atom bombardment (FAB) and continuous flow-FAB (CF-FAB) interfaces were developed in 1985 and 1986 respectively. Both interfaces were similar, but they differed in that the first used a porous frit probe as connecting channel, while CF-FAB used a probe tip. From these, the CF-FAB was more successful as a LC–MS interface and was useful to analyze non-volatile and thermally labile compounds. In these interfaces, the LC effluent passed through the frit or CF-FAB channels to form a uniform liquid film at the tip. There, the liquid was bombarded with ion beams or high energy atoms (fast atoms). For stable operation, the FAB based interfaces were able to handle liquid flow rates of only 1–15 μl and were also restricted to microbore and capillary columns. In order to be used in FAB MS ionization sources, the analytes of interest had to be mixed with a matrix (e.g., glycerol) that could be added before or after the separation in the LC column. FAB based interfaces were extensively used to characterize peptides, but lost applicability with the advent of electrospray based interfaces in 1988.
A break in the murder case of "Motamed" occurred when prosecutors got their hands-on text messages after they were able to unlock a decrypted cell phone from one of the participants in the plot. The two hitmen were discovered to have extensive criminal records and longstanding ties to organised crime. The text messages showed they were monitoring "Motamed", and had no clue why he was targeted, only that they were assigned with the task and were eager to get the job done. In April 2019, they were sentenced to 25 and 20 years of imprisonment for their roles in the murder. The messages also implicated "Noffel", who was found guilty for ordering the murder and sentenced to life in prison for his involvement in this hit. However, all three suspects remain silent about any of their involvement in this case. Dutch investigators were baffled when it became clear that the killers of "Motamed" were working on the orders of the Dutch-Moroccan crime boss "Noffel", a close associate of Ridouan Taghi. The Dutch government sees "Motamed" as the link between Taghi and the Iranian secret service. However, the execution of Mohammad-Reza Kolahi ("Ali Motamed") was not the only murder in which the Dutch government accuses Iran of being involved in. In 2017, an assassin shot several bullets into Ahmad Mola Nissi, the leader of the Iranian separatist group Arab Struggle Movement for the Liberation of Ahwaz. Nissi died in front of his house in The Hague, after living in the Netherlands for over a decade.
== Function == Microproteins function as post-translational regulators. Microproteins disrupt the formation of heterodimeric, homodimeric, or multimeric complexes. Furthermore, microproteins can interact with any protein that requires functional dimers to function normally. The primary targets are transcription factors that bind to DNA as dimers. Microproteins regulate these complexes by creating homotypic dimers with the targets and inhibit protein complex function. The two types of miP inhibitions are: homotypic miP inhibition and heterotypic miP inhibition. In homotypic miP inhibition, microproteins interact with proteins with similar protein-protein interaction (PPI) domain. In heterotypic miP inhibition, microproteins interact with proteins with different but compatible PPI domain. In both types of inhibition, microproteins interfere and prevent the PPI domains from interacting with their normal proteins. Microproteins plays roles in biological process such as immunity and inflammation, cancer and cell cycle regulation, cellular transport, muscle and heart functions, gene expression and genome maintenance, proteostasis, and metabolic homeostasis.
Sources: en.wikipedia.org
=== Gastrointestinal === NSAIDs cause an increase in the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients are at greater risk for serious gastrointestinal events.
28 September – Following a trial at the High Court in Stirling, Christopher McGowan, 28, is found guilty of the murder of Claire Inglis, his girlfriend who he battered and strangled, before burning her with a lighter and pushing a wet wipe down her throat. 29 September – Two Scottish postmasters convicted of embezzlement because of a faulty computer system have their convictions posthumously overturned by the Court of Criminal Appeal in Edinburgh. An office manager is awarded £37,000 by an industrial tribunal after her boss told her she used the menopause as an "excuse for everything". Two people are treated in hospital after a collision involving the Flying Scotsman locomotive and Royal Scotsman train at Aviemore railway station.
==== Initial use ==== Moisture can cause mold and spoilage in many items. It can also damage electronics by causing condensation and shorten the lifespan of chemicals, like those in vitamins. Silica gel packets help by absorbing moisture and extending the life of these items. Silica gel may also be used to keep the relative humidity inside a high frequency radio or satellite transmission system waveguide as low as possible (see also humidity buffering). Excessive moisture buildup within a waveguide can cause arcing inside the waveguide itself, damaging the power amplifier feeding it. Also, the beads of water that form and condense inside the waveguide change the characteristic impedance and frequency, degrading the signal. It is common for a small compressed air system (similar to a small home aquarium pump) to be employed to circulate the air inside the waveguide over a jar of silica gel. Silica gel is also used to dry the air in industrial compressed air systems. Air from the compressor discharge flows through a bed of silica gel beads. The silica gel adsorbs moisture from the air, preventing damage at the point of use of the compressed air due to condensation or moisture. The same system is used to dry the compressed air on railway locomotives, where condensation and ice in the brake air pipes can lead to brake failure.
Every building material contains traces of natural radioactive substances, especially 238uranium, 232thorium, and their decay products, and 40potassium. Solidified and effusive rocks such as granite, tuff, and pumice have higher levels of radioactivity. In contrast, sand, gravel, limestone, and natural gypsum (calcium sulfate dihydrate) have low levels of radioactivity. The European Union's Activity Concentration Index (ACI), developed in 1999, can be used to assess radiation exposure from building materials. It replaces the Leningrad summation formula, which was used in 1971 in Leningrad (St. Petersburg) to determine how much radiation exposure from building materials is permissible for humans. The ACI is calculated from the sum of the weighted activities of 40potassium, 226radium, and 232thorium. The weighting takes into account the relative harmfulness to humans. According to official recommendations, building materials with a European ACI value greater than "1" should not be used in large quantities.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.